Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance

BACKGROUND/AIMS: Golimumab (GLM) is an anti-tumor necrosis factor-α drug approved for treating moderate-to-severe active ulcerative colitis (UC). A 52-week post-marketing surveillance (PMS) was initiated to evaluate its safety and effectiveness in patients with UC in Japan. We present an interim rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Shiro, Asano, Teita, Tsuchiya, Hiroaki, Sugimoto, Kanami, Imai, Yuya, Yokoyama, Seiji, Suzuki, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344245/
https://www.ncbi.nlm.nih.gov/pubmed/34333910
http://dx.doi.org/10.5217/ir.2021.00032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344245/
https://www.ncbi.nlm.nih.gov/pubmed/34333910
http://dx.doi.org/10.5217/ir.2021.00032

Ejemplares similares